Inspire Medical Systems, Inc. will release its financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. The company’s management team will host a conference call at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Investors can access the live webcast of the call through the Investor Relations page of the Inspire website. For those intending to ask questions during the call, registration is required to receive dial-in details and a unique access code. The company recommends registering at least 10 minutes before the start time to ensure connectivity.

A replay of the conference call will be available on the company’s Investor Relations website approximately two hours after the event. The replay will remain archived on the site for two weeks.

Conference Call Details

Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea. Its proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.

Freedom Capital Markets analyst Keith Hinton has initiated coverage on Inspire Medical Systems with a Buy rating and announced a price target of $62. The rating comes as the company continues to navigate operational challenges and ongoing legal scrutiny regarding its device launches and financial guidance.

The new Buy rating contrasts with recent analyst actions, including a downgrade by Evercore ISI Group analyst Daniel Markowitz to In-Line from Outperform, alongside a reduction in the price target to $40 from $55. Inspire Medical Systems trades on the NYSE under the ticker INSP.

Investigation and Guidance Cuts

Kahn Swick & Foti LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is continuing its investigation into Inspire Medical Systems regarding potential breaches of fiduciary duties by its officers and directors. The investigation follows significant disclosures regarding the launch of the Inspire V device and subsequent securities litigation.

In August 2025, Inspire Medical Systems revealed that the launch of its Inspire V device faced an "elongated timeframe" due to previously undisclosed issues. The company cited that many centers failed to complete required training, contracting, and onboarding criteria before purchasing and implanting the device. Additionally, software updates for claims submissions were delayed until early July, and excess inventory resulted in poor demand.

Consequently, the company slashed its 2025 earnings guidance by more than 80%. The guidance was reduced from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share. Following these disclosures, Inspire Medical Systems and certain executives were named in a securities class action lawsuit alleging violations of federal securities laws. The case has been transferred from the United States District Court for the Southern District of New York to the District of Minnesota and remains ongoing.

KSF is examining whether Inspire's officers and directors violated state or federal laws or failed to meet their fiduciary duties to shareholders. The firm is seeking information from long-term shareholders to discuss potential legal rights.